Fengxu Yu | Atrial Fibrillation | Best Researcher Award 

Posted on by Pencis

Fengxu Yu | Atrial Fibrillation | Best Researcher Award 

The Affiliated Hospital of Southwest Medical University | China

Author Profile:

Scopus

👨‍⚕️ MR. FENGXU YU – PIONEER IN CARDIOVASCULAR INNOVATION

🎓 EARLY ACADEMIC PURSUITS

Born in January 1976, Professor Fengxu Yu embarked on his medical journey with a strong academic foundation, earning his M.D. and later achieving qualifications as a doctoral supervisor. His passion for cardiovascular science led him to pursue postdoctoral training in France, equipping him with a global perspective and refined clinical research skills. This international exposure laid the groundwork for his future leadership in complex cardiovascular research and surgical practice.

💼 PROFESSIONAL ENDEAVORS

Currently serving as a Professor at The Affiliated Hospital of Southwest Medical University, Dr. Yu holds several distinguished roles:

  • Standing Committee Member, Cardiac Surgery Committee (CAMEA)

  • Committee Member, Heart Valve Committee (CRHA)

  • Vice Chair, Sichuan Thoracic & Cardiac Surgery Association

  • Academic Leader, recognized by the Sichuan Health Commission

  • Member, Asian Heart Valve Society, China Chapter

  • Recipient, Luzhou Top Talent Award

His consistent dedication has cemented his role as a leading figure in thoracic and cardiac surgery across China.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON ATRIAL FIBRILLATION

Dr. Yu’s research endeavors focus on molecular and biomechanical mechanisms in cardiovascular disease, especially atrial fibrillation (AF), atherosclerosis, and aortic dissection. His current areas of exploration include:

  • Non-coding RNAs (e.g., circRNA/ceRNA networks) in AF pathogenesis

  • Application of induced pluripotent stem cells in modeling AF

  • Effects of shear stress on vascular endothelial health and its link to atherosclerosis

Through these efforts, Dr. Yu bridges basic science with clinical relevance, advancing the future of personalized medicine.

📊 IMPACT AND INFLUENCE

As a principal investigator, Dr. Yu has led nearly 20 major research projects funded by provincial and municipal institutions. He has also contributed to 30+ collaborative studies as a lead or co-investigator. His academic output includes over 50 peer-reviewed publications, with 12 articles indexed in SCI journals and 20+ papers in national core journals, showcasing his thought leadership in cardiovascular science.

📚 SELECTED RESEARCH PROJECTS

Some of Dr. Yu’s notable funded projects include:

  • Mechanism of Shear Stress-Downregulated Annexin A1 (2019)

  • circRNA-Regulated ceRNA Networks in AF (2025)

  • Personalized Warfarin Therapy Post-Valve Replacement (2022)

  • Hsa_circ_0025573—miR-133b—MMP9 in AF Pathogenesis (2022)

  • SRB1-Mediated Endothelial Injury in Atherosclerosis (2018)

These projects reflect a multidisciplinary approach to understanding and treating cardiovascular conditions.

🏅 ACADEMIC CITES AND MEMBERSHIPS

Professor Yu actively contributes to national and international academic bodies. His memberships include:

  • CAMEA – Cardiac Surgery Committee

  • CRHA – Heart Valve Committee

  • Sichuan Thoracic & Cardiac Surgery Association

  • Asian Heart Valve Society – China Chapter

These affiliations enhance his visibility in shaping future cardiac surgery standards and innovations.

🌟 LEGACY AND FUTURE CONTRIBUTIONS

Professor Fengxu Yu is a mentor, innovator, and academic leader. His mentorship of graduate students, collaboration with international institutions such as Heidelberg University, and continued work on translational research ensure a legacy of impactful science. As cardiovascular disease remains a global challenge, his pioneering work in non-coding RNA and biomechanical interactions is poised to redefine prevention and treatment strategies.

📑 NOTABLE PUBLICATIONS

"Myocardial infarction serum preconditioning bone marrow mesenchymal stem cell-derived exosomes enhance anti-fibrosis in rat myocardial infarction hearts" 

Authors: Y., Gan, Yang , C., Wang, Changyi , R., Liao, Ruili , ... H., Liu, Hui , Y., Fu, Yong
Journal: Molecular and Cellular Biochemistry.
Year: 2025

"Identification of the optimal reference genes for atrial fibrillation model established by iPSC-derived atrial myocytes" 

Authors: L., Li, Lei , Z., Zhao, Zijuan , Z., Liu, Zihao , ... Y., Nie, Yongmei , F., Yu, Fengxu
Journal: BMC Genomics
Year: 2024

"Postoperative delirium prediction after cardiac surgery using machine learning models" 

Authors: T., Yang, Tan , H., Yang, Hai , Y., Liu, Yan , ... Y., Zhang, Ying , F., Yu, Fengxu
Journal: Computers in Biology and Medicine
Year: 2024

Dongling Liu | TCM Pharmacology & Safety Research | Best Researcher Award

Posted on by Pencis

Prof. Dr. Dongling Liu | TCM Pharmacology & Safety Research | Best Researcher Award

Gansu University Of Chinese Medicine | China

Author Profile

Scopus

Google Scholar

🌟 PROF. DR. DONGLING LIU: A TRAILBLAZER IN CARDIOVASCULAR PHARMACOLOGY AND TCM INNOVATION

🎓 EARLY ACADEMIC PURSUITS

Professor Dongling Liu began her academic journey with a Bachelor of Science in Pharmacy from Lanzhou University (2003–2007). Driven by a passion for pharmacological research, she pursued her Master’s and Ph.D. in Microbial Pharmacy at the same university, completing her doctorate in 2013. These formative years laid the foundation for her expertise in cardiovascular pharmacology and traditional Chinese medicine (TCM).

👩‍🏫 PROFESSIONAL ENDEAVORS

In September 2013, Professor Liu joined the School of Pharmacy at Gansu University of Chinese Medicine, progressing through roles from Lecturer to Professor. She is also the Vice President of the Longyao Industrial Innovation Research Institute since December 2023. Her global exposure includes research stints as a Visiting Scholar at UC San Diego and Training at Sydney Medical School, which have broadened her scientific perspective and collaborative network.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON TCM PHARMACOLOGY & SAFETY RESEARCH

With a specialization in cardiovascular pharmacology, Professor Liu has led four NSFC projects, primarily exploring molecular mechanisms behind doxorubicin-induced cardiotoxicity and the cardioprotective effects of TCM compounds. Her team’s discovery on kaempferol’s inhibition of mitochondrial ROS-dependent ferroptosis has opened new avenues in drug development, bridging traditional medicine with modern pharmacological science.

📚 IMPACT AND INFLUENCE

Professor Liu’s academic impact includes 40+ publications, 10+ in SCI-indexed journals, and 24 indexed in Scopus/Web of Science/PubMed. Her cumulative impact factor over the last 3 years is 29.1, with an H-index of 8 (Scopus ID: 57216257824). She has also secured 4 patents (8 pending) and published a reference book.

🏆 ACADEMIC CITES AND RECOGNITION

Her research contributions have earned prestigious awards including the First Prize of Gansu Provincial Science & Technology Progress Award, the Huangfu Mi TCM Science Award, and recognition such as the Gansu Outstanding Youth Fund, Feitian Youth Scholar, and Longyuan Talent Award. She serves as a peer reviewer for NSFC and is a member of multiple national academic committees.

🌍 COLLABORATIONS, PROJECTS & EXTENSION WORK

Professor Liu has completed 5 research projects, is actively engaged in 3 ongoing projects, and has collaborated on 20+ national and regional grants. She has led 2 consultancy/industry-sponsored projects worth $300,000 USD, and maintains functional MoUs with 2 institutions. As an extension leader, she directed policy reforms and standardization of Gansu's proprietary “Longyao” TCM materials, trained farmers, and established a health product demonstration base.

🎤 CONFERENCES, TALKS AND EDITORIAL ROLES

She has presented at 20 conferences, delivered 10 invited talks, and organized 20 workshops and conferences. She holds 3 editorial appointments, reflecting her expertise and reputation in pharmacological research.

🎓 RESEARCH SCHOLAR DEVELOPMENT

To date, Professor Liu has mentored 8 research scholars to graduation and currently supervises 5 ongoing doctoral candidates, contributing significantly to the cultivation of future pharmacology experts.

🔮 LEGACY AND FUTURE CONTRIBUTIONS

Professor Liu is not only a distinguished educator and researcher but also a visionary in innovative TCM-based pharmacotherapy. Her ongoing efforts aim to integrate traditional Chinese formulations with modern therapeutic standards, thereby contributing to global healthcare innovation. Her work ensures a lasting legacy in cardiovascular pharmacology, policy reform, and rural health development.

📑 NOTABLE PUBLICATIONS

"Exploring the efficacy and mechanism of Qingxuan decoction in treating opioid-induced constipation" 

Authors: Y., Zhang, Yarong , H., Cao, Haoshi , L., Su, Linling , ... D., Liu, Dongling , Y., Hai, Yang
Journal: Pharmacological Research - Modern Chinese Medicine
Year: 2025

"Effect of shenmai injection on anthracycline-induced cardiotoxicity: A systematic review and meta-analysis" 

Authors: Lili Yang, Xiaorui Liu,  Wen Yang,  Siqi Wang,  Zimu Li,  Yiming Lei,  Dongling Liu
Journal: Health Sciences
Year: 2024

Xu Zhichen | Esophageal Cancer | Best Research Article Award

Posted on by Pencis

Dr. Xu Zhichen | Esophageal Cancer | Best Research Article Award

First Hospital of Quanzhou Affiliated to Fujian Medical University | China

Author Profile:

Scopus

👨‍⚕️ XU ZHICHEN: DEDICATED HEALER AND ESOPHAGEAL CANCER RESEARCHER

📚 EARLY ACADEMIC PURSUITS

Xu Zhichen was born in Putian, belonging to the Han ethnic group. His journey into the world of medicine began with a Bachelor's degree in Clinical Neurology from Luzhou Medical College (2005–2010). Demonstrating a strong passion for advancing cancer treatment, he pursued a Master’s degree in Radiation Oncology at Fujian Medical University (2010–2013), focusing on Radiotherapy. His formal education laid a solid foundation for a career devoted to battling cancer, particularly esophageal cancer.

🏥 PROFESSIONAL ENDEAVORS

Following his master’s program, Xu Zhichen completed standardized clinical training at Quanzhou First Hospital (2013.9–2014.9). In September 2014, he officially joined the Radiotherapy Department at the same institution, where he continues to serve with distinction as an Associate Chief Physician. His dedication and skill have earned him certifications at every level of practice, including:

  • Practicing Physician Certificate (2016)

  • Official Appointment (2018)

  • Vice Senior Certification in Radiotherapy (2024)

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON ESOPHAGEAL CANCER

Dr. Xu Zhichen is a recognized specialist in esophageal cancer, with his clinical and research efforts focusing on radiotherapy advancements. His notable academic contributions include:

  • Leading one provincial and one municipal research project.

  • Publishing 1 CSCD-indexed paper, 2 SCI-indexed papers, and multiple provincial-level papers.

These publications highlight his continuous effort to innovate and improve therapeutic strategies in radiation oncology.

🌐 IMPACT AND INFLUENCE

Dr. Xu’s influence extends beyond the clinic. He is a prominent figure in academic and professional circles:

  • Selected for the "Hundred Talent Program" at Quanzhou First Hospital – a mark of distinction for emerging medical leaders.

  • Serves as a Member of the Youth Committee of the Fujian Radiation Oncology Society, where he contributes to shaping policies and mentoring young oncologists.

📊 ACADEMIC CITES AND RECOGNITION

Though still in the early stages of senior-level research contribution, Dr. Xu’s SCI and CSCD publications have gained attention in the oncology community. His work is regularly cited in Chinese medical journals focused on radiotherapy protocols and esophageal cancer treatment methodologies, underlining his growing academic footprint.

🌟 LEGACY AND FUTURE CONTRIBUTIONS

With a decade of focused clinical experience and increasing research output, Dr. Xu Zhichen is set to become a leading voice in radiation oncology in Fujian Province and beyond. His blend of practical excellence, academic commitment, and institutional leadership signals a promising trajectory. Future expectations include:

  • Expansion into multi-institutional clinical trials on esophageal cancer.

  • Publishing in high-impact international journals.

  • Training and mentoring the next generation of radiation oncologists.

📑 NOTABLE PUBLICATIONS

"A dynamic nomogram for predicting abdominal lymph node recurrence in patients with esophageal carcinoma" 

Authors: Z., Xu, Zhichen , B., Su, Baoan , M., Lin, Mingqiang , Q., Xu, Qinghua , M., Qu, Mengke
Journal: Scientific Reports
Year: 2025

Heng Zhang | Cardiology | Best Researcher Award

Posted on by Pencis

Dr. Heng Zhang | Cardiology | Best Researcher Award

Fuwai Hospital, National Center for Cardiovascular Diseases | China

Author Profile

Scopus

Orcid ID

HENG ZHANG, M.D., PH.D. 🩺🫀

Dr. Heng Zhang is a distinguished medical professional specializing in cardiovascular surgery, with substantial contributions to the field of cardiovascular disease research, clinical practice, and health innovation. Holding a dual degree in medicine (M.D.) and a doctorate in philosophy (Ph.D.), Dr. Zhang’s academic and professional endeavors continue to shape the landscape of modern cardiovascular surgery, offering valuable insights into risk prediction, coronary revascularization, and the optimization of treatment strategies for cardiovascular diseases. His current role as an Associate Chief Physician at Fuwai Hospital, National Clinical Research Center of Cardiovascular Diseases, further cements his impact on the advancement of medical science.

EARLY ACADEMIC PURSUITS 🎓

Dr. Heng Zhang's academic journey began with an M.D. degree from Tianjin Medical University, where he graduated in 2010. During his studies, Dr. Zhang displayed a keen interest in cardiovascular health, which led him to pursue a Ph.D. in Cardiovascular Disease from Peking Union Medical College in 2015. Throughout his academic path, he also participated in key research exchanges, including a Visiting Scholar program in the USA at Duke Clinical Research Institute, further broadening his expertise in cardiovascular outcomes research and clinical performance measures.

PROFESSIONAL ENDEAVORS 👨‍⚕️🏥

Dr. Zhang’s clinical training began in 2009 with an internship at Nankai Hospital and continued through various stages of residency, including Peking Union Medical College Hospital and Fuwai Hospital. By 2015, he began specializing in cardiovascular surgery, eventually becoming an Attending Physician at Fuwai Hospital in 2019. His extensive clinical exposure includes pediatric and adult cardiac surgery, where he gained invaluable experience in treating complex heart conditions and improving patient outcomes through innovative surgical techniques.

CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOLOGY🔬💡

Dr. Zhang’s research has primarily focused on cardiovascular surgery registry, coronary revascularization risk prediction, and optimizing diagnostic and treatment strategies for cardiovascular conditions. He is deeply engaged in cardiovascular outcomes research, with particular attention to improving clinical performance measures and treatment protocols for heart diseases.

As the principal investigator and host of multiple high-impact research projects, Dr. Zhang has led groundbreaking studies such as evaluating the efficacy and safety of RN medications in preventing myocardial injury caused by ischemia-reperfusion and examining macrophage subtypes in coronary atherosclerosis. He has also significantly contributed to understanding valve replacement surgery and the long-term effects of heart valve interventions.

IMPACT AND INFLUENCE 🌍💪

Dr. Zhang's contributions to cardiovascular medicine have left a profound mark on clinical practice and research. Through his involvement in various research grants, including National Key Research and Development Plans of China and the Natural Science Foundation of China, Dr. Zhang has been pivotal in advancing both the theoretical and practical aspects of cardiovascular disease treatment and prevention. His work has also led to a shift in how cardiovascular surgeries are approached, particularly regarding patient-specific interventions in coronary artery malformation and atrial fibrillation.

His research projects have earned him several prestigious accolades, such as the Outstanding Reviewer for the Chinese Clinical Journal of Thoracic and Cardiovascular Surgery and the American Heart Association Travel Stipend Award. Dr. Zhang’s clinical and academic contributions are shaping future medical protocols, paving the way for a more personalized approach to heart disease treatment.

ACADEMIC CITES & HONORS 🏅📚

Dr. Zhang’s academic excellence is reflected not only in his research citations but also in the numerous honors and scholarships he has received. These include multiple first prizes for Young Investigator Awards, outstanding doctoral dissertations, and recognitions for clinical excellence. His impressive list of awards, including the Beijing Science and Technology Award (2016) and the Outstanding Doctoral Dissertation from Peking Union Medical College (2016), highlights his leadership and commitment to medical innovation.

LEGACY AND FUTURE CONTRIBUTIONS 🔮🏅

Dr. Zhang’s legacy lies in his consistent drive to innovate and advance cardiovascular surgery. His work with various research institutions and medical centers has laid a robust foundation for the continued improvement of heart disease diagnosis and treatment. As a principal investigator for several key projects and his role on editorial boards such as the Journal of American Heart Association, Dr. Zhang is poised to influence future cardiovascular research and practice for years to come.

Looking ahead, his research into heart valve replacement and atrial fibrillation is expected to lead to new clinical strategies that will enhance patient care globally. His future contributions are expected to redefine approaches to cardiovascular health, with an emphasis on personalized medicine and novel surgical techniques.

FINAL THOUGHTS 🧠💖

Dr. Heng Zhang is a leading figure in cardiovascular medicine, combining clinical expertise with cutting-edge research to make significant advancements in heart disease treatment. His future is one of continued excellence and innovation, as he works tirelessly to shape the future of cardiovascular care, improving the lives of patients worldwide.

NOTABLE PUBLICATIONS 📑

"Impact of remnant cholesterol on short-term and long-term prognosis in patients with prediabetes or diabetes undergoing coronary artery bypass grafting: a large-scale cohort study" 

  • Authors: Z., Li, Zhongchen , C., Yu, Chunyu , H., Zhang, Heng , Y., Zhao, Yan , Z., Zheng, Zhe
  • Journal: Cardiovascular Diabetology
  • Year: 2025

"Association of stress hyperglycemia ratio with short-term and long-term prognosis in patients undergoing coronary artery bypass grafting across different glucose metabolism states: a large-scale cohort study" 

  • Authors: Z., Li, Zhongchen , R., Chen, Runze , Z., Zeng, Zhiwei , H., Zhang, Heng , Z., Zheng, Zhe
  • Journal: Cardiovascular Diabetology
  • Year: 2025

"Clinical Outcomes of Surgical Revascularization Strategies Guided by Quantitative Flow Ratio in Primary Noncoronary Cardiac Surgery" 

  • Authors: L., Li, Linlin , H., Zhang, Heng , C., Rao, Chenfei , C., Liu, Chang , H., Fan, Hongguang
  • Journal: Journal of Thoracic Imaging
  • Year: 2024

"Association of carotid duplex ultrasonography screening with stroke and mortality among patients undergoing coronary artery bypass grafting" 

  • Authors: H., Zhang, Heng , D., Zhang, Danwei , J., Qu, Jianyu , X., Qian, Xiangyang , Z., Zheng, Zhe
  • Journal: Journal of Vascular Surgery
  • Year: 2024

"Impact of High Lipoprotein(a) on Long-Term Survival Following Coronary Artery Bypass Grafting" 

  • Authors: S., Yuan, Shuo , F., Li, Fangzhou , H., Zhang, Heng , Y., Zhao, Yan , Z., Zheng, Zhe
  • Journal: Journal of the American Heart Association
  • Year: 2024